Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?

Skedgel, C, Rayson, D and Younis, T (2013) Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer? Annals of Oncology, 24 (7). pp. 1834-40. ISSN 0923-7534

Full text not available from this repository. (Request a copy)

Abstract

In light of clinical uncertainty and the high acquisition costs of trastuzumab, we examined the value for money associated with concurrent or sequential trastuzumab in women with HER-2/neu-positive breast cancer with small node-negative tumours (T1bN0).

Item Type: Article
Uncontrolled Keywords: adult,aged,aged 80 and over,antibodies, monoclonal humanized),antineoplastic agents,breast neoplasms,chemotherapy (adjuvant),cost-benefit analysis,female,humans,middle aged,models (economic),neoplasm recurrence (local),neoplasm staging,quality-adjusted life years,receptor (erbb-2),risk,treatment outcome
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 21 Jan 2015 12:46
Last Modified: 21 Apr 2020 23:47
URI: https://ueaeprints.uea.ac.uk/id/eprint/51921
DOI: 10.1093/annonc/mdt069

Actions (login required)

View Item View Item